{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:32:25Z","timestamp":1765960345923,"version":"3.37.3"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bone.2024.117280","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T13:40:21Z","timestamp":1728567621000},"page":"117280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparison of PET\/CT versus CT only in the assessment of new heterotopic ossification bone lesions in patients with fibrodysplasia ossificans progressiva"],"prefix":"10.1016","volume":"190","author":[{"given":"Dinko","family":"Gonz\u00e1lez Trotter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"McGinniss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kusha","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bret J.","family":"Musser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary A.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Mellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aris N.","family":"Economides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bone.2024.117280_bb0005","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1385\/BMM:3:3-4:201","article-title":"The genetics of fibrodysplasia ossificans progressiva","volume":"3","author":"Shore","year":"2005","journal-title":"Clin. Rev. Bone Miner. Metab."},{"issue":"1","key":"10.1016\/j.bone.2024.117280_bb0010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13023-019-1068-7","article-title":"Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes","volume":"14","author":"Pignolo","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.bone.2024.117280_bb0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2106\/00004623-199302000-00008","article-title":"The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva","volume":"75","author":"Cohen","year":"1993","journal-title":"A study of forty-four patients, J Bone Joint Surg Am"},{"issue":"6","key":"10.1016\/j.bone.2024.117280_bb0020","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11832-015-0704-6","article-title":"Quality of life of patients with fibrodysplasia ossificans progressiva","volume":"9","author":"Ortiz-Agapito","year":"2015","journal-title":"J. Child. Orthop."},{"issue":"3","key":"10.1016\/j.bone.2024.117280_bb0025","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/jbmr.2728","article-title":"The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment","volume":"31","author":"Pignolo","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"303","key":"10.1016\/j.bone.2024.117280_bb0030","doi-asserted-by":"crossref","first-page":"303ra137","DOI":"10.1126\/scitranslmed.aac4358","article-title":"ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin a","volume":"7","author":"Hatsell","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"50","key":"10.1016\/j.bone.2024.117280_bb0035","doi-asserted-by":"crossref","first-page":"15438","DOI":"10.1073\/pnas.1510540112","article-title":"Neofunction of ACVR1 in fibrodysplasia ossificans progressiva","volume":"112","author":"Hino","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bone.2024.117280_bb0040","volume":"9","author":"Aykul","year":"2020","journal-title":"Activin A forms a non-signaling complex with ACVR1 and type II Activin\/BMP receptors via its finger 2 tip loop, eLife"},{"issue":"1","key":"10.1016\/j.bone.2024.117280_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2967\/jnumed.116.184028","article-title":"Total-body PET: maximizing sensitivity to create new opportunities for clinical research and patient care","volume":"59","author":"Cherry","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.bone.2024.117280_bb0050","first-page":"321","article-title":"Use of PET\/CT scanning in cancer patients: technical and practical considerations","volume":"18","author":"Griffeth","year":"2005","journal-title":"Proc. (Bayl. Univ. Med. Cent.)"},{"issue":"5","key":"10.1016\/j.bone.2024.117280_bb0055","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1148\/rg.345130061","article-title":"Newer PET application with an old tracer: role of 18F-NaF skeletal PET\/CT in oncologic practice","volume":"34","author":"Bastawrous","year":"2014","journal-title":"Radiographics"},{"issue":"7","key":"10.1016\/j.bone.2024.117280_bb0060","first-page":"1091","article-title":"Assessment of porcine bone metabolism by dynamic","volume":"42","author":"Piert","year":"2001","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.bone.2024.117280_bb0065","first-page":"949","article-title":"Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry","volume":"77","author":"Messa","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2024.117280_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2019.03.009","article-title":"Evolution of heterotopic bone in fibrodysplasia ossificans progressiva: an [18F]NaF PET\/CT study","volume":"124","author":"Botman","year":"2019","journal-title":"Bone"},{"issue":"12","key":"10.1016\/j.bone.2024.117280_bb0075","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.gim.2022.08.013","article-title":"The natural history of fibrodysplasia ossificans progressiva: a prospective, global 36-month study","volume":"24","author":"Pignolo","year":"2022","journal-title":"Genet. Med."},{"key":"10.1016\/j.bone.2024.117280_bb0080","first-page":"113","article-title":"Monitoring and management of fibrodysplasia ossificans progressiva: current perspectives","volume":"14","author":"Smilde","year":"2022","journal-title":"Orthop. Res. Rev."},{"issue":"10","key":"10.1016\/j.bone.2024.117280_bb0085","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/jbmr.4655","article-title":"Palovarotene for fibrodysplasia ossificans progressiva (FOP): results of a randomized, placebo-controlled, double-blind phase 2 trial","volume":"37","author":"Pignolo","year":"2022","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2024.117280_bb0090","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1038\/s41591-023-02561-8","article-title":"Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"29","author":"Di Rocco","year":"2023","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.bone.2024.117280_bb0095","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/jbmr\/zjae140","article-title":"Characterization of flare-ups and impact of Garetosmab in adults with Fibrodysplasia Ossificans Progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial","volume":"39","author":"Keen","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2024.117280_bb0100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bone.2017.08.012","article-title":"[18F]NaF PET\/CT scan as an early marker of heterotopic ossification in fibrodysplasia ossificans progressiva","volume":"109","author":"Eekhoff","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.bone.2024.117280_bb0105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1750-1172-8-163","article-title":"Perhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: an open-labeled clinical trial","volume":"8","author":"Kitoh","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.bone.2024.117280_bb0110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jbm4.10008","article-title":"Flare up after maxillofacial surgery in a patient with fibrodysplasia ossificans progressiva: an [18F] NaF PET\/CT study and a systematic review","volume":"2","author":"Eekhoff","year":"2017","journal-title":"JBMR Plus"},{"issue":"4","key":"10.1016\/j.bone.2024.117280_bb0115","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.21037\/qims-20-788","article-title":"Clinical utility of F-18 sodium fluoride PET\/CT for estimating disease activity in patients with rheumatoid arthritis","volume":"11","author":"Park","year":"2021","journal-title":"Quant. Imaging Med. Surg."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328224002692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328224002692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T04:08:40Z","timestamp":1735445320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328224002692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":23,"alternative-id":["S8756328224002692"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2024.117280","relation":{},"ISSN":["8756-3282"],"issn-type":[{"type":"print","value":"8756-3282"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of PET\/CT versus CT only in the assessment of new heterotopic ossification bone lesions in patients with fibrodysplasia ossificans progressiva","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2024.117280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Regeneron Pharmaceuticals, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117280"}}